SNCE SCIENCE 37 HLDGS INC

Science 37 to Report Second Quarter 2023 Financial Results on August 8, 2023

Science 37 to Report Second Quarter 2023 Financial Results on August 8, 2023

RESEARCH TRIANGLE PARK, N.C., July 25, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™ today announced it will report second quarter 2023 financial results prior to the market open on Tuesday, August 8, 2023.

The Science 37 management team will host a conference call to discuss these results on August 8, 2023, at 8:30 a.m. Eastern Time. The call can be accessed by dialing 1-877-269-7751 (toll-free domestic) or 1-201-389-0908 (international) and using the Conference ID 13739329 or by utilizing the Call me™ feature using this to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Science 37 website. A replay of the webcast will be available for approximately 90 days.

About Science 37

Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to accelerate clinical research by enabling universal trial access for patients. Through our Metasite™ we reach an expanded population beyond the traditional site, delivering on our goal of clinical research that works for everyone—with greater patient diversity. Patients gain the flexibility to participate from the comfort of their own homes, at their local community provider, or at a traditional site when needed. Our Metasite is powered by a proprietary technology platform with in-house medical and operational experts that drive uniform study orchestration, enabling greater compliance and high-quality data. To learn more, visit , or email .

Contacts:

MEDIA INQUIRIES:

Grazia Mohren

Science 37

Email:

INVESTOR RELATIONS:

Steve Halper

LifeSci Advisors

Email:



EN
25/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCIENCE 37 HLDGS INC

 PRESS RELEASE

Science 37 Completes Second FDA Inspection as Enrollment Leader in Pha...

Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial MORRISVILLE, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, today announced the successful completion of its second FDA inspection, reaffirming the quality of its Direct-to-Patient Site for clinical research. The inspection resulted in a No Action Indicated (NAI) categorization, with no objectionable conditions noted and no Form 483 issued. Led by Science 37's internal Quality Assurance & Compliance team, the inspection focused on the company’s role...

 PRESS RELEASE

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-...

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation Seasoned Strategist and Former Chief Commercial Officer Poised to Accelerate Access and Equity in Clinical Research MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company’s Chief Commercial Officer, Van Horn’s appointment follows his pivotal role in driving operational excellence and shaping the company’s strategic direction to better prioritize client ...

 PRESS RELEASE

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease...

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical company, . The hepatology study of an investigational medicine for cholestatic pruritus in primary biliary cholangitis (PBC) required 230 global participants, of which Science 37 was able to contribute almost half (17 - 47%) of the U.S. enrollment for the study. Recognizing that t...

 PRESS RELEASE

Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Aw...

Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Decentralized Clinical Trials Top Honor Recognizes Science 37’s Visionary Innovation, Market-Leading Performance, and Unmatched Customer Care in the Decentralized Clinical Trials Industry MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Today, , a leader in enhancing patient access to clinical trials, announced that it has received Frost & Sullivan’s 2024 Global Company of the Year Award. Recognizing the market participant that exemplifies visionary innovation, market-leading performance, and unmatched cu...

 PRESS RELEASE

Science 37 Unveils New Corporate Headquarters in Research Triangle Par...

Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC 19,000-square-foot facility reflects the company’s recent growth and continued commitment to the region MORRISVILLE, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, today announced the grand opening of its new, 19,000-square-foot corporate headquarters in Morrisville, North Carolina, in the heart of Research Triangle Park. The new, state-of-the-art facility, will serve as a hub for all Science 37 operations, enabling cross-functional teams with greater opportun...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch